Clinical characteristics of dysplasia in UC and the correlation between dysplasia and UC recurrence

Rongli Liu; Jing Luan; Qianbo Dong; Mingwei You; Yuanming Kang; Wenyan Wang; Hongli Liu; Liqun Yan

doi:10.48101/ujms.v131.13676

Rongli Liu Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China https://orcid.org/0009-0009-4523-7443
Jing Luan Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China https://orcid.org/0000-0002-1722-193X
Qianbo Dong Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China https://orcid.org/0000-0003-4746-1819
Mingwei You Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China https://orcid.org/0009-0001-3861-8266
Yuanming Kang Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China https://orcid.org/0009-0009-1287-7030
Wenyan Wang Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China https://orcid.org/0009-0004-0644-8030
Hongli Liu Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China
Liqun Yan Department of Medical Imaging, Luquan Branch, The Second Hospital of Hebei Medical University, Shijiazhuang, China

DOI: https://doi.org/10.48101/ujms.v131.13676

Keywords: Ulcerative colitis, Dysplasia, Influencing factors, Recurrence, Correlation

Abstract

Objective: This research aims to identify the main influencing factors for dysplasia in ulcerative colitis (UC) patients and explored the correlation between dysplasia and the recurrence frequency of UC.

Methods: This study retrospectively included 348 UC patients from the outpatient clinic of the Second Hospital of Hebei Medical University between December 2021 and December 2023 as the research subjects. The UC patients were divided into the dysplasia group and the non-dysplasia group based on pathological results. The general data and clinical data of the two groups were compared, and the typical computed tomography enterography (CTE) imaging features of the patients in the dysplasia group were explored. The main influencing factors for the occurrence of dysplasia in patients were screened using the univariate logistic regression analysis method and the ridge regression analysis method. All the follow-up data of the research subjects were complete, the recurrence situations of UC in the two groups were compared. The correlation between dysplasia and the recurrence frequency of UC was analysed using the Spearman rank correlation coefficient.

Results: This study found that there were statistically significant differences in indicators such as disease classification, disease severity, lesion extent, disease activity degree, and faecal calprotectin (FC) level between the two groups of patients. Patients with dysplasia presented usually with CTE imaging features of mesenteric lymphadenopathy, mucosal abnormal enhancement, and bowel wall thickening. Univariate logistic regression revealed that the above indicators were influencing factors for dysplasia in UC patients (P < 0.05). Collinearity test and ridge regression analysis showed that chronic continuous type/acute fulminant type disease classification, severe disease severity, E3 lesion range, moderately active stage/severely active stage of disease activity degree, and high FC level would increase the possibility of dysplasia (P < 0.05). The recurrence rate of UC diseases in the dysplasia group was higher than that in the non-dysplasia group, and recurrence types were also different (P < 0.05). Spearman rank correlation analysis indicated that the grade of dysplasia, disease severity, lesion range, and degree of disease activity were positively correlated with recurrence frequency of UC (P < 0.05).

Conclusion: Disease classification, disease severity, lesion extent, disease activity degree, and FC were independently correlated with occurrence of dysplasia in UC patients. Moreover, dysplasia increased the probability of patient recurrence. The grade of dysplasia and related influencing factors showed a positive correlation with the recurrence frequency of UC.

Downloads

Download data is not yet available.

References

1.
Gurvits GE. Ulcerative colitis in the elderly. Intern Emerg Med. 2025,20:1281–2. doi: https://doi.org/10.1007/s11739-024-03798-y

2.
Savio MC, Coelho CJ, Oliveira E, Oliveira Magro D, Valverde DA, Quaresma AB, et al. Nationwide trends in colectomy rates for ulcerative colitis in Brazil: an analysis of the unified public healthcare system. Gastroenterol Hepatol. 2025,48:502434. doi: https://doi.org/10.1016/j.gastrohep.2025.502434

3.
Yamazaki M, Chung H, Xu Y, Qiu H. International journal of colorectal disease. Trends in the prevalence and incidence of ulcerative colitis in Japan and the US. Int J Colorectal Dis. 2023,38:135. doi: https://doi.org/10.1007/s00384-023-04417-6

4.
Gorospe J, Windsor J, Hracs L, Coward S, Buie M, Quan J, et al. Trends in inflammatory bowel disease incidence and prevalence across epidemiologic stages: a global systematic review with mate analysis. Inflamm Bowel Dis. 2024,166:2. doi: https://doi.org/10.1093/ibd/izae020.085

5.
Harindranath S, Singh A. Tofacitinib in ulcerative colitis – in the era of precision medicine. Dig Liver Dis. 2024,56:909–10. doi: https://doi.org/10.1016/j.dld.2024.01.188

6.
Altuwaijiri M, Alharbi O, AlRuthia Y, Aljebreen AM, Almadi MA, et al. P323 the rate of and risk of dysplasia in long standing ulcerative colitis patients among middle-eastern population. J Crohns Colitis. 2023,17:462–2. doi: https://doi.org/10.1093/ecco-jcc/jjac190.0453.

7.
Singh K, Khoury AA, Kurti Z, Reinglas J, Verdon C, et al. P150 High adherence to surveillance guidelines in IBD results in low CRC and dysplasia rates, while rates of dysplasia and cancer are low before the suggested start of surveillance. Results from a tertiary IBD centre. J Crohns Colitis. 2019,17:164–165 doi: https://doi.org/10.1093/ecco-jcc/jjy222.274

8.
Zhang J, Chen C, Yan W, Fu Y. New sights of immunometabolism and agent progress in colitis associated colorectal cancer. Front Pharmacol. 2023,14:1303913. doi: https://doi.org/10.3389/fphar.2023.1303913

9.
Zhang YL, Yang SS, Liu YS, Yan SG. Progress in prevention and treatment of dysplasia in ulcerative colitis based on Cyclooxygenase-2/p53 axis. Acta Acad Med Sin. 2024,46:940–8. doi: https://doi.org/10.3881/j.issn.1000-503X.15911

10.
Zhu XL, Xie L. Retrospective analysis of relevant influencing factors for the occurrence of dysplasia in the patients with ulcerative colitis. Mod Dig Interv. 2022,27:160–3. doi: https://doi.org/10.3969/j.issn.1672-2159.2022.02.007

11.
Li R, Yang L. Research progress in the combined treatment of ulcerative colitis. Rev Esp de Enferm Dig. 2025,117:129–35. doi: https://doi.org/10.17235/reed.2023.9444/2022

12.
Nguyen KM, Wright EK. Vancomycin and ustekinumab combination therapy in acute ulcerative colitis. ACG Case Rep J. 2024,11:1302–52. doi: https://doi.org/10.14309/crj.0000000000001302

13.
Leoncini G, Ronchetti S, Villanacci V. Mucosal barrier dysfunction and relapse in ulcerative colitis: is there more that meets the eye? Dig Liver Dis. 2024,56:1420. doi: https://doi.org/10.1016/j.dld.2024.04.028

14.
Wu KC, Chen MH, Qian JM. Chinese clinical practice guideline on the management of ulcerative colitis (2023, Xi′an). Chin J Gastroenterol. 2024,29:145–73. doi: https://doi.org/10.3969/j.issn.1008-7125.2024.03.003

15.
Xiao SY, Ye ZY. Recommendations on pathological diagnosis of inflammatory bowel disease associated dysplasia. Chin J Gastroenterol. 2022,27:463–9. doi: https://doi.org/10.3969/j.issn.1008-7125.2022.08.003

16.
Ahmed EA, Elatty KA, Mahdy RE, Emara DM, Header DA. Computed tomography enterocolongraphy in assessment of degree of ulcerative colitis activity. Int J Clin Pract. 2021,75:14626. doi: https://doi.org/10.1111/ijcp.14626

17.
Liu GN. Analysis of related Imaging scores of 83 patients with ulcerative colitis with multislice spiral CT enterography and Its correlation with inflammation. Inn Mong Med J. 2022,54:281–3. doi: https://doi.org/10.16096/J.cnki.nmgyxzz.2022.54.03.009

18.
Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis. 2018,22:298–317. doi: https://doi.org/10.1111/1751-2980.12994

19.
Riviere P, Li W S, Chaparro M, De Cruz P, Spinelli A, Laharie D. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol. 2024,9:251–62. doi: https://doi.org/10.1016/S2468-1253(23)00313-8

20.
Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology. 2022,162:715–30. doi: https://doi.org/10.1053/j.gastro.2021.10.035

21.
Sanat ZM, Vahedi H, Malekzadeh R, Kasaeian A, Ganjaroudi NM, Sima A, et al. Causes of colectomy in patients with ulcerative colitis: findings from an Iranian National Registry. Arch Iran Med. 2024,27:350–6. doi: https://doi.org/10.34172/aim.28887

22.
Nishio M, Kunisaki R, Shibata W, Ajioka Y, Hirasawa K, Takase A, et al. Serrated polyps in patients with ulcerative colitis: unique clinicopathological and biological characteristics. PLoS One. 2023,18:0282204. doi: https://doi.org/10.1371/journal.pone.0282204

23.
Sakamoto K, Okabayashi K, Seishima R, Shigeta K, Kiyohara H, Mikami Y, et al. Radiomics prediction of surgery in ulcerative colitis refractory to medical treatment. Tech Coloproctol. 2025,29:113. doi: https://doi.org/10.1007/s10151-025-03139-x

24.
Tabarsi NT, Mortazavi N, Norouzi A, Norouzi A, Besharat S, Behnampour N, et al. Association of oral manifestations with severity of the disease in ulcerative colitis patients. BMC Gastroenterol. 2024,24:1–7. doi: https://doi.org/10.1186/s12876-024-03472-9

25.
Shinozaki M, Kobayashi K, Kunisaki R, Hisamatsu T, Naganuma M, Takahashi K-I, et al. Surveillance for dysplasia in patients with ulcerative colitis: discrepancy between guidelines and practice. Dig Endosc. 2017,29:584–93. doi: https://doi.org/10.1111/den.12803

26.
Bhama AR, Kapadia MR. Management of dysplasia in ulcerative colitis. J Laparoendosc Adv Surg Tech A. 2021,31:855–60. doi: https://doi.org/10.1089/lap.2020.0974

27.
Zhang R, Wang D, Lauwers GY, Choi WT. Increased active inflammation in the colon is not a reliable predictor of an elevated risk of dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Am J Surg Pathol. 2024,48:1154–63. doi: https://doi.org/10.1097/PAS.0000000000002255

28.
Aboelmaged WA, Abdelhalym ASA, Eltabbakh MMM, Omar YNA, et al. Evaluation of role of beta 2 microglobulin and P-ANCA in the diagnosis of ulcerative colitis and their correlation to disease activity. QJM. 2020,113:hcaa069.003. doi: https://doi.org/10.1093/qjmed/hcaa069.003

29.
Mannucci A, D’amico F, Saadi AE, Peyrin-Biroulet L, Danese S. Filgotinib for moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2022,16:927–40. doi: https://doi.org/10.1080/17474124.2022.2138857

30.
Nakov R, Velikova T, Nakov V, Ianiro G, Gerova V, Tankova L. Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis. Eur Rev Med Pharmacol Sci. 2019,31:788–94. doi: https://doi.org/10.26355/eurrev_201901_16893

31.
Hamed EFA, Mostafa NE, Farag SM, Ibrahim MN, Ibrahim BH, Rashed HE, et al. Human protozoa infection and dysplasia in ulcerative colitis: a neglected aspect in a prominent disease. Parasitol Res. 2023,122:2709–18. doi: https://doi.org/10.1007/s00436-023-07972-7

32.
Bhala N, Hart A, Watts D, Lewis S, Ghosh S, Hansell C, et al. Disease activity, burden and suffering in patients with ulcerative colitis in the UK cohort recruited into the global ICONIC study. Frontline Gastroenterol. 2023,14:25–31. doi: https://doi.org/10.1136/flgastro-2022-102104

33.
Lu XY, Zhang SL, Li XF, Li HY. Research advance on the interaction between gut microbes and cytokines in inflammatory bowel disease. Chin J Cell Mol Immunol. 2024,40:655–9. doi: https://doi.org/10.13423/j.cnki.cjcmi.009723

34.
Hebert-Milette I, Levesque C, Paquette J, Rivard ME, Villeneuve L, Boucher G, et al. Inflammatory bowel disease risk gene C1ORF106 regulates actin dynamics in intestinal epithelial cells. Biorxiv, 2025,14:643205. doi: https://doi.org/10.1101/2025.03.14.643205

35.
Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025,120:1187–224. doi: https://doi.org/10.14309/ajg.0000000000003463